News
The global injection pen market is set to witness a growth rate of 7% in the next 5 years. Rising prevalence of chronic ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ ...
TipRanks on MSN4d
Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma TreatmentPfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback